- MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability.
- Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin.
- Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system.
- The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.
Multiple sclerosis (“MS”) treatment has traditionally focused on controlling the immune activity that drives new inflammatory lesions and relapses. While this approach has transformed the management of relapsing MS, growing attention is being directed toward another fundamental challenge: protecting the nervous system from the damage that can accumulate over time and contribute to disability progression.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS, an oral, first-in-class new chemical entity designed to address demyelination through a fundamentally different therapeutic approach. Rather than primarily suppressing or depleting immune cells, Lucid-MS is being developed to protect myelin and inhibit processes that contribute to its degradation.
Beyond Inflammation: The Next Challenge in MS
The MS treatment landscape is evolving as researchers seek to address disease mechanisms that are not fully controlled by conventional anti-inflammatory therapies. New approaches include therapies designed to modulate specific immune pathways, as well as emerging strategies focused on neuroprotection, myelin preservation and repair.
BTK inhibitors are one example of the continued evolution of immune-directed treatment. These therapies are being investigated for their ability to influence B-cell and myeloid-cell signaling and potentially address inflammatory activity within the central nervous system. However, the broader direction of MS research extends beyond immune modulation alone.
The central challenge is that reducing new inflammatory activity does not necessarily restore tissue that has already been damaged. This has created growing interest in therapies that could directly protect myelin and nerve tissue and potentially address mechanisms contributing to progressive disability.
Myelin Protection and Repair Remain an Unmet Need
Myelin is the insulating material surrounding nerve fibers that allows electrical signals to travel efficiently through the nervous system. Damage to myelin is a defining feature of MS and can ultimately contribute to loss of neurological function.
Despite major advances in disease-modifying therapy, no approved MS therapy has yet established a clinically meaningful ability to restore previously damaged myelin. Research into remyelination and neuroprotection has therefore become an important area of drug development.
Results from experimental remyelination approaches have been mixed. The Cambridge CCMR-Two trial evaluating clemastine plus metformin produced findings consistent with a biological remyelination effect but did not demonstrate improvement in vision or disability over the study period. Other experimental approaches, including PIPE-307, have failed to demonstrate efficacy in clinical trials.
These challenges highlight the difficulty of translating promising biological mechanisms into clinically meaningful recovery — and the need for new approaches that can protect myelin before irreversible neural injury occurs.
Lucid-MS: A Different Approach
This is the scientific challenge Quantum BioPharma’s Lucid-MS program is designed to address. Lucid-MS is a patented new chemical entity being developed for multiple sclerosis. Preclinical studies reported by Quantum have demonstrated inhibition of myelin degradation, preservation of myelin and functional recovery in animal models of MS.
Importantly, Lucid-MS is being developed as a non-immunomodulatory approach. Rather than relying on broad immune suppression or immune-cell depletion, the program is intended to target a mechanism involved in myelin degradation.
This distinction could be particularly important in progressive MS, where disability can continue to accumulate even when overt inflammatory activity is reduced. The potential significance of this approach is not that it replaces existing disease-modifying therapies, but that it could ultimately address a different component of MS biology, one more directly related to myelin integrity and neuroprotection.
Advancing from Phase 1 to Phase 2
Quantum BioPharma has now reached an important clinical-development milestone. Following completion of phase 1 clinical studies in healthy volunteers, the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a planned phase 2 study of Lucid-MS. The phase 1 program provided clinical safety and pharmacokinetic information to support advancement into patient testing.
The FDA has subsequently cleared the Lucid-MS program to proceed with the planned phase 2 clinical trial. This regulatory milestone allows Quantum to advance Lucid-MS from early clinical development into a study designed to evaluate its safety, tolerability and potential efficacy in people with multiple sclerosis.
The phase 2 program represents an important transition for Lucid-MS. For the first time, the therapeutic hypothesis underlying myelin protection and inhibition of demyelination will be evaluated directly in people living with MS.
Measuring Myelin and Disease Biology
Quantum has also been building capabilities to support the clinical evaluation of myelin biology. In June 2025, the company announced that the first person with MS had been scanned in a joint study with Massachusetts General Hospital scientists involving a PET imaging technique designed to evaluate myelin integrity and demyelination.
The tracer, developed by Dr. Pedro Brugarolas and collaborators at Massachusetts General Hospital and Harvard Medical School, has been investigated for its ability to distinguish differences associated with myelin integrity. Such imaging approaches could ultimately provide researchers with additional tools for evaluating changes in myelin during clinical development. For programs focused on neuroprotection and myelin preservation, the ability to measure changes in the underlying biology of the disease could be particularly valuable alongside conventional clinical and MRI outcomes.
A New Opportunity in Progressive MS
The broader MS field is increasingly recognizing that controlling inflammation is only one part of addressing the disease. Existing disease-modifying therapies have substantially improved the ability to reduce relapses and inflammatory disease activity. However, disability progression can occur through mechanisms that are not completely explained by relapses or conventional inflammatory activity.
This creates an opportunity for therapies that target additional components of MS pathology. Quantum BioPharma’s Lucid-MS program is positioned around this opportunity: protecting myelin, inhibiting demyelination and potentially addressing a mechanism contributing to neurological deterioration without suppressing the immune system.
With FDA clearance now received to begin the phase 2 clinical trial, Quantum is moving from preclinical and early clinical development toward testing this therapeutic hypothesis directly in patients. The outcome of the phase 2 study will be important in determining whether the promising preclinical findings associated with Lucid-MS can translate into meaningful biological and clinical effects in people with MS. For Quantum, this represents the next major step in developing a potentially differentiated approach to multiple sclerosis — one focused not solely on suppressing inflammation but on protecting the nervous system itself.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN